Nina Mann1, Slim Mzoughi2,3, Ronen Schneider1, Susanne J Kühl4, Denny Schanze5, Verena Klämbt1, Svjetlana Lovric1, Youying Mao1, Shasha Shi6, Weizhen Tan1, Michael Kühl4, Ana C Onuchic-Whitford1,7, Ernestine Treimer8, Thomas M Kitzler1, Franziska Kause1, Sven Schumann8, Makiko Nakayama1, Florian Buerger1, Shirlee Shril1, Amelie T van der Ven1, Amar J Majmundar1, Kristina Marie Holton9, Amy Kolb1, Daniela A Braun1, Jia Rao1, Tilman Jobst-Schwan1, Eva Mildenberger10, Thomas Lennert11, Alma Kuechler12, Dagmar Wieczorek13, Oliver Gross14, Beate Ermisch-Omran15, Anja Werberger4, Martin Skalej16, Andreas R Janecke17, Neveen A Soliman18,19, Shrikant M Mane20, Richard P Lifton20,21, Jan Kadlec6, Ernesto Guccione2,3, Michael J Schmeisser8,22, Martin Zenker23, Friedhelm Hildebrandt24. 1. Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Methyltransferases in Development and Disease Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore. 3. Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Institute of Biochemistry and Molecular Biology, Ulm University, Ulm, Germany. 5. Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany. 6. Grenoble Alpes University, National Center for Scientific Research (CNRS), French Alternative Energies and Atomic Energy Commission (CEA), Institute of Structural Biology, Grenoble, France. 7. Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Institute for Microscopic Anatomy and Neurobiology, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany. 9. Research Computing, Harvard Medical School, Boston, Massachusetts. 10. Division of Neonatology, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany. 11. Department of Pediatrics, Charité - Universitätsmedizin Berlin, Berlin, Germany. 12. Institute of Human Genetics, University of Duisburg-Essen, Essen, Germany. 13. Institute of Human Genetics, Faculty of Medicine, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 14. Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany. 15. Department of Pediatric Nephrology, University Children's Hospital, Münster, Germany. 16. Institute of Neuroradiology, Otto von Guericke University Magdeburg, Magdeburg, Germany. 17. Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria. 18. Department of Pediatrics, Center of Pediatric Nephrology and Transplantation, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt. 19. The Egyption Group for Orphan Renal Diseases (EGORD), Cairo, Egypt. 20. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut. 21. Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, New York. 22. Focus Program Translational Neurosciences, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany. 23. Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany martin.zenker@med.ovgu.de friedhelm.hildebrandt@childrens.harvard.edu. 24. Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts martin.zenker@med.ovgu.de friedhelm.hildebrandt@childrens.harvard.edu.
Abstract
BACKGROUND: Galloway-Mowat syndrome (GAMOS) is characterized by neurodevelopmental defects and a progressive nephropathy, which typically manifests as steroid-resistant nephrotic syndrome. The prognosis of GAMOS is poor, and the majority of children progress to renal failure. The discovery of monogenic causes of GAMOS has uncovered molecular pathways involved in the pathogenesis of disease. METHODS: Homozygosity mapping, whole-exome sequencing, and linkage analysis were used to identify mutations in four families with a GAMOS-like phenotype, and high-throughput PCR technology was applied to 91 individuals with GAMOS and 816 individuals with isolated nephrotic syndrome. In vitro and in vivo studies determined the functional significance of the mutations identified. RESULTS: Three biallelic variants of the transcriptional regulator PRDM15 were detected in six families with proteinuric kidney disease. Four families with a variant in the protein's zinc-finger (ZNF) domain have additional GAMOS-like features, including brain anomalies, cardiac defects, and skeletal defects. All variants destabilize the PRDM15 protein, and the ZNF variant additionally interferes with transcriptional activation. Morpholino oligonucleotide-mediated knockdown of Prdm15 in Xenopus embryos disrupted pronephric development. Human wild-type PRDM15 RNA rescued the disruption, but the three PRDM15 variants did not. Finally, CRISPR-mediated knockout of PRDM15 in human podocytes led to dysregulation of several renal developmental genes. CONCLUSIONS: Variants in PRDM15 can cause either isolated nephrotic syndrome or a GAMOS-type syndrome on an allelic basis. PRDM15 regulates multiple developmental kidney genes, and is likely to play an essential role in renal development in humans.
BACKGROUND: Galloway-Mowat syndrome (GAMOS) is characterized by neurodevelopmental defects and a progressive nephropathy, which typically manifests as steroid-resistant nephrotic syndrome. The prognosis of GAMOS is poor, and the majority of children progress to renal failure. The discovery of monogenic causes of GAMOS has uncovered molecular pathways involved in the pathogenesis of disease. METHODS: Homozygosity mapping, whole-exome sequencing, and linkage analysis were used to identify mutations in four families with a GAMOS-like phenotype, and high-throughput PCR technology was applied to 91 individuals with GAMOS and 816 individuals with isolated nephrotic syndrome. In vitro and in vivo studies determined the functional significance of the mutations identified. RESULTS: Three biallelic variants of the transcriptional regulator PRDM15 were detected in six families with proteinuric kidney disease. Four families with a variant in the protein's zinc-finger (ZNF) domain have additional GAMOS-like features, including brain anomalies, cardiac defects, and skeletal defects. All variants destabilize the PRDM15 protein, and the ZNF variant additionally interferes with transcriptional activation. Morpholino oligonucleotide-mediated knockdown of Prdm15 in Xenopus embryos disrupted pronephric development. Human wild-type PRDM15 RNA rescued the disruption, but the three PRDM15 variants did not. Finally, CRISPR-mediated knockout of PRDM15 in human podocytes led to dysregulation of several renal developmental genes. CONCLUSIONS: Variants in PRDM15 can cause either isolated nephrotic syndrome or a GAMOS-type syndrome on an allelic basis. PRDM15 regulates multiple developmental kidney genes, and is likely to play an essential role in renal development in humans.
Authors: Kimberly J Reidy; Guillermo Villegas; Jason Teichman; Delma Veron; Wa Shen; Juan Jimenez; David Thomas; Alda Tufro Journal: Development Date: 2009-12 Impact factor: 6.868
Authors: Thiruvur Niranjan; Bernhard Bielesz; Antje Gruenwald; Manish P Ponda; Jeffrey B Kopp; David B Thomas; Katalin Susztak Journal: Nat Med Date: 2008-03-02 Impact factor: 53.440
Authors: Friedhelm Hildebrandt; Saskia F Heeringa; Franz Rüschendorf; Massimo Attanasio; Gudrun Nürnberg; Christian Becker; Dominik Seelow; Norbert Huebner; Gil Chernin; Christopher N Vlangos; Weibin Zhou; John F O'Toole; Bethan E Hoskins; Matthias T F Wolf; Bernward G Hinkes; Hassan Chaib; Shazia Ashraf; Dominik S Schoeb; Bugsu Ovunc; Susan J Allen; Virginia Vega-Warner; Eric Wise; Heather M Harville; Robert H Lyons; Joseph Washburn; James Macdonald; Peter Nürnberg; Edgar A Otto Journal: PLoS Genet Date: 2009-01-23 Impact factor: 5.917
Authors: Daniela Raciti; Luca Reggiani; Lars Geffers; Qiuhong Jiang; Francesca Bacchion; Astrid E Subrizi; Dave Clements; Christopher Tindal; Duncan R Davidson; Brigitte Kaissling; André W Brändli Journal: Genome Biol Date: 2008-05-20 Impact factor: 13.583
Authors: Slim Mzoughi; Federico Di Tullio; Diana H P Low; Corina-Mihaela Motofeanu; Sheena L M Ong; Heike Wollmann; Cheng Mun Wun; Paul Kruszka; Maximilian Muenke; Friedhelm Hildebrandt; N Ray Dunn; Daniel M Messerschmidt; Ernesto Guccione Journal: Sci Adv Date: 2020-01-10 Impact factor: 14.136
Authors: Malak Ali Alghamdi; Hicham Benabdelkamel; Afshan Masood; Narjes Saheb Sharif-Askari; Mahmood Y Hachim; Hamad Alsheikh; Muddathir H Hamad; Mustafa A Salih; Fahad A Bashiri; Khalid Alhasan; Tarek Kashour; Pilar Guatibonza Moreno; Sabine Schröder; Vasiliki Karageorgou; Aida M Bertoli-Avella; Hisham Alkhalidi; Dima Z Jamjoom; Ibrahim A Alorainy; Assim A Alfadda; Rabih Halwani Journal: Front Genet Date: 2022-06-23 Impact factor: 4.772